Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice)
Putra Gunawan, I Made Rian
Unknown Affiliation
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Olaparib As Therapy For Metastatic-Castration Resistant Prostate Cancer : Systematic Review And Meta Analysis Putra Gunawan, I Made Rian; Herawati, Fauna; Kirtishanti, Aguslina
Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Vol 11, No 1 (2024): February
Publisher : Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33508/jfst.v11i1.5284

Abstract

Prostate cancer is the second most prevalent cancer in men with approximately 1.4 million men worldwide. The main therapy for prostate cancer is androgen deprivation therapy (ADT), but patients who have received ADT may experience a condition of castration resistant prostate cancer (CRPC). More than 84% of patients have metastasized when diagnosed with CRPC (mCRPC) and median survival about 36 months. The Food & Drugs Association (FDA) has approved a new therapy for mCRPC patients, an example is olaparib. The purpose of this systematic review and meta analysis is to assess effectiveness (overall survival) and safety of olaparib in mCRPC. This research is using randomized control trial’s (RCT) article. The literature search process was carried out using the PubMed database. The quality of inclusion was assessed using the Critical Appraisal Skill Program (CASP) checklist and journal reputation. The results of the meta-analysis on the effectiveness of olaparib has showed that there was no significant difference in the patient's overall survival rate (RR=0. 81; 95% CI=0.58-1.13). The results of the meta analysis on the safety level of olaparib has showed a significant difference, seen from the side effects such as anemia (RR=3.47; 95% CI=2.59-4.65), nausea (RR=2.05; 95% CI=1.62-2.60) and fatigue (RR=1.32; 95% CI=1.10-1.59). The conclusion is olaparib as mCRPC therapy does not show significant effectiveness in improving overall survival in mCRPC. In addition, the low safety level of olaparib in mCRPC patients were seen from side effects such as anemia, nausea and fatigue
Olaparib As Therapy For Metastatic-Castration Resistant Prostate Cancer : Systematic Review And Meta Analysis Putra Gunawan, I Made Rian; Herawati, Fauna; Kirtishanti, Aguslina
Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Vol. 11 No. 1 (2024): February
Publisher : Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33508/jfst.v11i1.5284

Abstract

Prostate cancer is the second most prevalent cancer in men with approximately 1.4 million men worldwide. The main therapy for prostate cancer is androgen deprivation therapy (ADT), but patients who have received ADT may experience a condition of castration resistant prostate cancer (CRPC). More than 84% of patients have metastasized when diagnosed with CRPC (mCRPC) and median survival about 36 months. The Food & Drugs Association (FDA) has approved a new therapy for mCRPC patients, an example is olaparib. The purpose of this systematic review and meta analysis is to assess effectiveness (overall survival) and safety of olaparib in mCRPC. This research is using randomized control trial’s (RCT) article. The literature search process was carried out using the PubMed database. The quality of inclusion was assessed using the Critical Appraisal Skill Program (CASP) checklist and journal reputation. The results of the meta-analysis on the effectiveness of olaparib has showed that there was no significant difference in the patient's overall survival rate (RR=0. 81; 95% CI=0.58-1.13). The results of the meta analysis on the safety level of olaparib has showed a significant difference, seen from the side effects such as anemia (RR=3.47; 95% CI=2.59-4.65), nausea (RR=2.05; 95% CI=1.62-2.60) and fatigue (RR=1.32; 95% CI=1.10-1.59). The conclusion is olaparib as mCRPC therapy does not show significant effectiveness in improving overall survival in mCRPC. In addition, the low safety level of olaparib in mCRPC patients were seen from side effects such as anemia, nausea and fatigue
Co-Authors Aguslina Kirtishanti Herawati, Fauna